Title: Elagolix Treatment for Up to 12 Months in Women With Heavy Menstrual Bleeding and Uterine Leiomyomas.
Authors: Simon, James A; Al-Hendy, Ayman; Archer, David F; Barnhart, Kurt T; Bradley, Linda D; Carr, Bruce R; Dayspring, Thomas; Feinberg, Eve C; Gillispie, Veronica; Hurtado, Sandra; Kim, JinHee; Liu, Ran; Owens, Charlotte D; Muneyyirci-Delale, Ozgul; Wang, Alice; Watts, Nelson B; Schlaff, William D
Published In Obstet Gynecol, (2020 06)
Abstract: OBJECTIVE: To investigate the safety and efficacy of elagolix, an oral gonadotropin-releasing hormone antagonist, with hormonal add-back therapy for up to 12 months in women with heavy menstrual bleeding associated with uterine leiomyomas. METHODS: Elaris UF-EXTEND was a phase 3 extension study that evaluated an additional 6 months (up to 12 months total) of elagolix 300 mg twice daily with hormonal add-back therapy (estradiol 1 mg and norethindrone acetate 0.5 mg once daily) in women who completed an initial 6 months of the same treatment in one of two preceding phase 3 studies. The primary endpoint was the percentage of women with both less than 80 mL menstrual blood loss during final month and a 50% or greater reduction in menstrual blood loss from baseline to final month. Safety evaluations included adverse events and bone mineral density changes. The planned sample size of UF-EXTEND was based on estimated rollover and discontinuation rates in the two preceding studies. RESULTS: From September 2016 to March 2019, 433 women were enrolled in UF-EXTEND. Of these women, 218 received up to 12 months of elagolix with add-back therapy; the mean±SD age of this group was 42.4±5.4 years and 67.3% were black. The percentage of women who met the primary endpoint in this elagolix with add-back group was 87.9% (95% CI [83.4-92.3]). The most frequently reported adverse events with up to 12 months of elagolix plus add-back therapy were hot flush (6.9%), night sweats (3.2%), headache (5.5%), and nausea (4.1%). Mean percent decreases in bone mineral density from baseline to extension month 6 were significantly less with elagolix plus add-back therapy than with elagolix alone {between-group difference in lumbar spine: -3.3 (95% CI [-4.1 to -2.5])}. CONCLUSION: Up to 12 months of elagolix with add-back therapy provided sustained reduction in menstrual blood loss in women with uterine leiomyomas, with the addition of add-back therapy attenuating the hypoestrogenic effects of elagolix alone. No new or unexpected safety concerns were associated with an additional 6 months of elagolix with addback therapy. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov, NCT02925494. FUNDING SOURCE: AbbVie Inc funded this study.
PubMed ID:
32459423
MeSH Terms: Adult; Bone Density/drug effects; Double-Blind Method; Drug Therapy, Combination; Estradiol/administration & dosage*; Estradiol/adverse effects; Female; Gonadotropin-Releasing Hormone/antagonists & inhibitors; Headache/etiology; Hot Flashes/etiology; Humans; Hydrocarbons, Fluorinated/administration & dosage*; Hydrocarbons, Fluorinated/adverse effects; Leiomyoma/complications; Leiomyoma/drug therapy*; Leiomyoma/pathology; Menorrhagia/blood; Menorrhagia/drug therapy*; Menorrhagia/etiology; Middle Aged; Nausea/etiology; Norethindrone/administration & dosage*; Norethindrone/adverse effects; Pyrimidines/administration & dosage*; Pyrimidines/adverse effects; Quality of Life; Uterine Neoplasms/complications; Uterine Neoplasms/drug therapy*; Uterine Neoplasms/pathology